Last edition
News about "atopic dermatitis "
Lilly Gets FDA Approval for EBGLYSS for Atopic Dermatitis
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) approved EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis.
Atopic Dermatitis | 17/09/2024 | By Aishwarya
Johnson & Johnson to Acquire Proteologix to Expand its Portfolio
Johnson & Johnson has signed a definitive agreement to acquire Proteologix, Inc. for USD 850 million in cash, with the potential for an additional milestone payment.
Atopic Dermatitis | 17/05/2024 | By Aishwarya | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy